2025 Q4 -tulosraportti
Vain PDF
116 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·9 t sittenSharing this here, even though they are pursuing two different approaches, but with some overlap on car-t (I think Orna overlaps a bit more, but I'm unsure). Circio is directly exposed to AAV/ DNA gene therapy, which to me is a stroke of genius and which we now see unfolding through recent events. The interview is interesting for those particularly interested and they repeat some of what Wiklund says (a bit demanding with a lot of technical jargon): https://podcast.labiotech.eu/1995493/episodes/19591848-why-western-pharma-is-sleeping-on-china-s-circular-rna-revolution
Thanks, but now @Fattigstakkaren comes with a comment because you bring up something ancient from 7,August 2026 :-) (Ref. earlier, irony mixed in).
·10 t sittenA little off topic, but when the share price reaches kr 28 I have a very good Cognac that will be opened. So, the first milestone on this journey that will be rewarded.
·14 t sittenNew week is coming up - exciting as always. Let's keep it objective, Don't trash talk. Tone it down instead of resorting to personal attacks. Don't oversell yesterday's news! There's a lot of good in this forum, but the arguing we sometimes see is just too silly. Good luck with your stock market week 😊
The Facebook group seems extremely "behind the curve", doesn't it? Often posts news 2-3 days after publication, and discusses old updates. No offense intended, mind you - but little matches this forum, for better or worse.- ·1 päivä sitten · MuokattuCAR-T Has anyone seen the program on this? This is not ESGCT in October. "In-vivo CAR seems to have advanced significantly. At RNA Leaders USA on September 25, Circio has received its own 25-minute presentation with the very specific title «Advancing circRNA expression systems applied to in vivo CAR cell Therapy». Circio's own calendar mainly states only that they are participating in the conference; the detailed program reveals what they will actually present. It is a clear indication, but not proof, of a more mature data package"
18 t sittenTämä julkaisu on poistettu.This is bullshit, based on speculation and technological incompetence. Firstly, CAR-T is nothing new.. That more are now trying in vivo CAR-T is expected, but your major fallacy lies in the RNA technology itself. RiboX uses artificial (synthetic) circRNA which must be produced and circularized in a factory, and it is difficult to scale up and purify (CMC). In addition, RNA degrades, which means the effect wanes and requires repeated doses. Circio's circVec is not pre-made circRNA, but a DNA recipe. Our own cells produce our own circRNA from the inside, which provides a completely different and more long-lasting expression. This is what makes Circio an investment case.. That RiboX gets IND factory-made RNA and an RNA-specific LNP, does not change this The two companies utilize the technology in fundamentally different ways, and face completely different challenges. I naturally hope that Circio's method works, but we don't know that yet.. That's why we are waiting for readouts.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
116 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·9 t sittenSharing this here, even though they are pursuing two different approaches, but with some overlap on car-t (I think Orna overlaps a bit more, but I'm unsure). Circio is directly exposed to AAV/ DNA gene therapy, which to me is a stroke of genius and which we now see unfolding through recent events. The interview is interesting for those particularly interested and they repeat some of what Wiklund says (a bit demanding with a lot of technical jargon): https://podcast.labiotech.eu/1995493/episodes/19591848-why-western-pharma-is-sleeping-on-china-s-circular-rna-revolutionThanks, but now @Fattigstakkaren comes with a comment because you bring up something ancient from 7,August 2026 :-) (Ref. earlier, irony mixed in).
- ·10 t sittenA little off topic, but when the share price reaches kr 28 I have a very good Cognac that will be opened. So, the first milestone on this journey that will be rewarded.
- ·14 t sittenNew week is coming up - exciting as always. Let's keep it objective, Don't trash talk. Tone it down instead of resorting to personal attacks. Don't oversell yesterday's news! There's a lot of good in this forum, but the arguing we sometimes see is just too silly. Good luck with your stock market week 😊The Facebook group seems extremely "behind the curve", doesn't it? Often posts news 2-3 days after publication, and discusses old updates. No offense intended, mind you - but little matches this forum, for better or worse.
- ·1 päivä sitten · MuokattuCAR-T Has anyone seen the program on this? This is not ESGCT in October. "In-vivo CAR seems to have advanced significantly. At RNA Leaders USA on September 25, Circio has received its own 25-minute presentation with the very specific title «Advancing circRNA expression systems applied to in vivo CAR cell Therapy». Circio's own calendar mainly states only that they are participating in the conference; the detailed program reveals what they will actually present. It is a clear indication, but not proof, of a more mature data package"
- 18 t sittenTämä julkaisu on poistettu.This is bullshit, based on speculation and technological incompetence. Firstly, CAR-T is nothing new.. That more are now trying in vivo CAR-T is expected, but your major fallacy lies in the RNA technology itself. RiboX uses artificial (synthetic) circRNA which must be produced and circularized in a factory, and it is difficult to scale up and purify (CMC). In addition, RNA degrades, which means the effect wanes and requires repeated doses. Circio's circVec is not pre-made circRNA, but a DNA recipe. Our own cells produce our own circRNA from the inside, which provides a completely different and more long-lasting expression. This is what makes Circio an investment case.. That RiboX gets IND factory-made RNA and an RNA-specific LNP, does not change this The two companies utilize the technology in fundamentally different ways, and face completely different challenges. I naturally hope that Circio's method works, but we don't know that yet.. That's why we are waiting for readouts.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
116 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·9 t sittenSharing this here, even though they are pursuing two different approaches, but with some overlap on car-t (I think Orna overlaps a bit more, but I'm unsure). Circio is directly exposed to AAV/ DNA gene therapy, which to me is a stroke of genius and which we now see unfolding through recent events. The interview is interesting for those particularly interested and they repeat some of what Wiklund says (a bit demanding with a lot of technical jargon): https://podcast.labiotech.eu/1995493/episodes/19591848-why-western-pharma-is-sleeping-on-china-s-circular-rna-revolutionThanks, but now @Fattigstakkaren comes with a comment because you bring up something ancient from 7,August 2026 :-) (Ref. earlier, irony mixed in).
- ·10 t sittenA little off topic, but when the share price reaches kr 28 I have a very good Cognac that will be opened. So, the first milestone on this journey that will be rewarded.
- ·14 t sittenNew week is coming up - exciting as always. Let's keep it objective, Don't trash talk. Tone it down instead of resorting to personal attacks. Don't oversell yesterday's news! There's a lot of good in this forum, but the arguing we sometimes see is just too silly. Good luck with your stock market week 😊The Facebook group seems extremely "behind the curve", doesn't it? Often posts news 2-3 days after publication, and discusses old updates. No offense intended, mind you - but little matches this forum, for better or worse.
- ·1 päivä sitten · MuokattuCAR-T Has anyone seen the program on this? This is not ESGCT in October. "In-vivo CAR seems to have advanced significantly. At RNA Leaders USA on September 25, Circio has received its own 25-minute presentation with the very specific title «Advancing circRNA expression systems applied to in vivo CAR cell Therapy». Circio's own calendar mainly states only that they are participating in the conference; the detailed program reveals what they will actually present. It is a clear indication, but not proof, of a more mature data package"
- 18 t sittenTämä julkaisu on poistettu.This is bullshit, based on speculation and technological incompetence. Firstly, CAR-T is nothing new.. That more are now trying in vivo CAR-T is expected, but your major fallacy lies in the RNA technology itself. RiboX uses artificial (synthetic) circRNA which must be produced and circularized in a factory, and it is difficult to scale up and purify (CMC). In addition, RNA degrades, which means the effect wanes and requires repeated doses. Circio's circVec is not pre-made circRNA, but a DNA recipe. Our own cells produce our own circRNA from the inside, which provides a completely different and more long-lasting expression. This is what makes Circio an investment case.. That RiboX gets IND factory-made RNA and an RNA-specific LNP, does not change this The two companies utilize the technology in fundamentally different ways, and face completely different challenges. I naturally hope that Circio's method works, but we don't know that yet.. That's why we are waiting for readouts.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt